AVENIO ctDNA Expanded Kit

Overview

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).

Features and Benefits of AVENIO ctDNA Expanded Kit

  • Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Product Highlights

Accurate detection of all four classes of mutations with high sensitivity and specificity2,3

  • >99% sensitivity for all four classes of mutations
  • >99% positive predictive value (PPV) for indels, fusions and CNVs, and >98% PPV for SNVs

Profiling of a broad array of genes with a single assay kit

  • 77 assay targets in a single panel

A portfolio of NGS liquid biopsy assays  

The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring.

Specifications
Panel size
192 kb
Sample size
4 ml of plasma
cfDNA input
10-50 ng
Reactions per kit
16
Turn-around time
5 days from extraction to results